J. Lewicki

发表

Immunohistochemical localization of guanylate cyclase within neurons of rat brain.

M. A. Ariano, F. Murad, J. Lewicki, 1982, Proceedings of the National Academy of Sciences of the United States of America.

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

G. Sherlock, M. Clarke, K. Shedden, 2007, The New England journal of medicine.

Atrial Natriuretic Peptide

J. Lewicki, J. Baxter, D. Gardner, 1988, Bio/Technology.

Characterization of Recombinant Human Prorenin and Renin

J. Lewicki, J. Baxter, J. Vigne, 1988, HYPERTENSION.

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

M. Fischer, J. Lewicki, A. Gurney, 2012, Proceedings of the National Academy of Sciences.

Purification and subunit composition of atrial natriuretic peptide receptor.

J. Lewicki, D. Schenk, J. G. Porter, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Semi-preparative purification of recombinant human renin and prorenin.

J. Lewicki, M. Wong, C. Carilli, 1988, Journal of chromatography.

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

M. Fischer, J. Lewicki, A. Gurney, 2011, Cancer research.

Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors

Nicholas J. Wang, P. Spellman, L. V. van't Veer, 2012, Breast Cancer Research and Treatment.

Abstract 1907: Wnt pathway antagonist OMP-54F28 (FZD8-Fc) inhibits tumor growth and reduces tumor-initiating cell frequency in patient-derived hepatocellular carcinoma and ovarian cancer xenograft models

M. Fischer, J. Lewicki, A. Gurney, 2014 .

Abstract A30: Predictive and pharmacodynamic biomarkers of vantictumab (OMP-18R5; anti-Frizzled) in non-small cell lung cancer

M. Fischer, J. Lewicki, T. Hoey, 2015 .

Cloning of a cDNA encoding porcine brain natriuretic peptide.

J. Lewicki, J. Seilhamer, J. G. Porter, 1989, The Journal of biological chemistry.

Resolution of Multiple Forms of Human Angiotensinogen Isoelectric Focusing Heterogeneity Profile Analysis

J. Lewicki, M. Printz, J. Printz, 1977, Circulation research.

Isolation and functional expression of the human atrial natriuretic peptide clearance receptor cDNA.

J. Lewicki, J. G. Porter, A. Arfsten, 1990, Biochemical and biophysical research communications.

Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones.

J. Lewicki, D. Schenk, J. G. Porter, 1988, The Journal of biological chemistry.

Reversible inactivation of guanylate cyclase by mixed disulfide formation.

F. Murad, J. Lewicki, H. Brandwein, 1981, The Journal of biological chemistry.

Cloning and sequence analysis of the cDNA for the rat atrial natriuretic factor precursor

J. Fiddes, J. Laragh, J. Lewicki, 1984, Nature.

Clearance function of type C receptors of atrial natriuretic factor in rats.

J. Lewicki, R. Scarborough, T. Maack, 1989, The American journal of physiology.

C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells.

J. Lewicki, J. G. Porter, A. Protter, 1992, The American journal of physiology.

Human and canine gene homologs of porcine brain natriuretic peptide.

J. Lewicki, J. Seilhamer, J. G. Porter, 1989, Biochemical and biophysical research communications.

Distinct atrial natriuretic factor receptor sites on cultured bovine aortic smooth muscle and endothelial cells.

J. Lewicki, D. Schenk, R. Scarborough, 1985, Biochemical and biophysical research communications.

Truncated atrial natriuretic peptide analogs. Comparison between receptor binding and stimulation of cyclic GMP accumulation in cultured vascular smooth muscle cells.

J. Lewicki, D. Schenk, A. Arfsten, 1986, The Journal of biological chemistry.

Identification of atrial natriuretic factor gene transcripts in the central nervous system of the rat.

J. Fiddes, J. Lewicki, J. Baxter, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide

J. Laragh, J. Lewicki, A. Januszewicz, 1984, Nature.

Regional distribution of angiotensinogen in rat brain

J. Fallon, J. Lewicki, M. Printz, 1978, Brain Research.

Structure and analysis of the bovine atrial natriuretic peptide precursor gene.

J. Lewicki, G. Vlasuk, G. Bencen, 1986, Biochemical and biophysical research communications.

Extra-atrial expression of the gene for atrial natriuretic factor.

W. Ganong, J. Fiddes, J. Lewicki, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Isolation and Molecular Characterization of Cancer Stem Cells in MMTV‐Wnt‐1 Murine Breast Tumors

Gavin Sherlock, Kerby Shedden, Maximilian Diehn, 2008, Stem cells.

Renal mechanism of action of rat atrial natriuretic factor.

J. Lewicki, M. G. Cogan, L. Johnson, 1985, The Journal of clinical investigation.

Anti-DLL4 HasBroad SpectrumActivityinPancreatic Cancer DependentonTargetingDLL4-NotchSignalinginBothTumor and Vasculature Cells

Edward J. Kim, M. Fischer, J. Lewicki, 2012 .

Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure.

J. Lewicki, M. Redfield, J. Burnett, 1994, The American journal of physiology.

Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor.

J. Lewicki, G. Koh, T. Maack, 1992, The American journal of physiology.

Cloning, sequence analysis, and processing of the rat and human atrial natriuretic peptide precursors.

J. Fiddes, J. Lewicki, J. Baxter, 1986, Federation proceedings.

Expression and regulation of ANP receptor subtypes in rat renal glomeruli and papillae.

E. Martin, J. Lewicki, B. Ballermann, 1989, The American journal of physiology.

Recombinant expression of a secreted form of the atrial natriuretic peptide clearance receptor.

J. Lewicki, D. Schenk, J. G. Porter, 1989, The Journal of biological chemistry.

Identification of the receptor for atrial natriuretic factor on cultured vascular cells.

J. Lewicki, D. Schenk, J. G. Porter, 1985, The Journal of biological chemistry.

Effects of small C-ANF receptor ligands on plasma levels of atrial natriuretic factor, blood pressure, and renal function in the rat.

J. Lewicki, T. Maack, G. Mcenroe, 1991, Canadian journal of physiology and pharmacology.

Highly purified particulate guanylate cyclase from rat lung: characterization and comparison with soluble guanylate cyclase

F. Murad, S. Waldman, J. Lewicki, 2004, Molecular and Cellular Biochemistry.

Molecular Determinants of Natriuretic Peptide Clearance Receptor Function

J. Lewicki, A. Protter, 1997 .

Structural and Functional Relationships of Atrial Peptide Receptor Subtypes

J. Lewicki, J. G. Porter, F. Fuller, 1991 .

Biologic role of atrial natriuretic factor clearance receptor in congestive heart failure.

J. Lewicki, J. Burnett, M. Perrella, 1993, The American journal of physiology.

Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor.

J. Lewicki, D. Nussenzveig, T. Maack, 1990, The Journal of biological chemistry.

Hemodynamic effects of atrial natriuretic factor clearance receptor occupancy in conscious sheep.

J. Lewicki, D. Parkes, R. Scarborough, 1990, American journal of hypertension.

Physiological role of silent receptors of atrial natriuretic factor.

J. Lewicki, R. Scarborough, D. Nussenzveig, 1987, Science.

ANP-(7-23) stimulates a DHP-sensitive Ca2+ conductance and reduces cellular cAMP via a cGMP-independent mechanism.

P. Barrett, J. Lewicki, C. Isales, 1992, The American journal of physiology.

Antihypertensive and aldosterone-lowering effects of synthetic atrial natriuretic factor in renin-dependent renovascular hypertension.

J. Laragh, J. Lewicki, E. Vaughan, 1984, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Abstract 1549: Development and validation of a biomarker for prospective selection of Notch1 activation in patients with certain advanced solid tumors in a first-in-human phase1 study of the cancer stem cell targeting antibody OMP-52M51 (anti-Notch1)

J. Lewicki, T. Hoey, S. Anderson, 2015 .

Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution.

J D Baxter, M. James, M. Murphy, 1989, Science.

Nucleotide sequence of the gene encoding human atrial natriuretic factor precursor

J. Fiddes, J. Lewicki, B. Greenberg, 1984, Nature.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

Michael F Clarke, Sanjeev Satyal, M. Clarke, 2009, Cell stem cell.

Abstract A030: Biomarker study of vantictumab plus paclitaxel in HER2- breast cancer patients

J. Lewicki, F. Cattaruzza, G. Argast, 2018 .

WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death

M. Fischer, J. Lewicki, A. Gurney, 2017, Science Advances.

Abstract 4367: Discovery and evaluation of pharmacodynamic and predictive biomarkers for anti-RSPO3, a treatment that reduces tumor growth and cancer stem cell frequency in patient derived xenograft tumor models

M. Fischer, J. Lewicki, A. Gurney, 2015 .

Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy

M. Clarke, J. Lewicki, A. Gurney, 2008, PloS one.

RENIN SUBSTRATE IN THE CNS: POTENTIAL SIGNIFICANCE TO CENTRAL REGULATORY MECHANISMS

J. Lewicki, M. Printz, 1977 .

Clearance of rabbit plasma angiotensinogen and relationship to CSF angiotensinogen.

J. Lewicki, M. Printz, J. Printz, 1983, The American journal of physiology.

Abstract 4652: Effects of anti-DLL4 treatment on non-small cell lung cancer (NSCLC) human xenograft tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells

Edward J. Kim, M. Fischer, J. Lewicki, 2012, Clinical Cancer Research.

Correction: Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy

M. Clarke, J. Lewicki, A. Gurney, 2008, PLoS ONE.

Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4

D. Ho, Qiang Xu, G. Schoolnik, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Abstract 3357: Targeting cancer stem cells by an anti-DLL4 antibody inhibits epithelial-to-mesenchymal transition, delays tumor recurrence and overcomes drug resistance in breast and pancreatic cancer

M. Fischer, J. Lewicki, A. Gurney, 2012 .

Abstract 2834: Anti-DLL4 treatment inhibits melanoma tumor growth, recurrence, metastases, and reduces frequency of cancer stem cells in a clinically relevant tumor model in NOD/SCID mice

M. Fischer, J. Lewicki, A. Gurney, 2011 .

Monoclonal antibodies to surfactant proteins SP28-36 label canine type II and nonciliated bronchiolar cells by immunofluorescence.

J. Lewicki, D. Schenk, M. Williams, 1988, The American review of respiratory disease.

Lipid levels and peripheral vascular disease in diabetic and non-diabetic subjects.

J. Lewicki, J. Best, P. G. Matthews, 1998, Atherosclerosis.

Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.

J. Lewicki, G. Schreiner, S. Chakravarty, 2003, Bioorganic & medicinal chemistry letters.

Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide.

J. Lewicki, J. Burnett, L. Aarhus, 1995, The American journal of physiology.

D-amino acid-substituted atrial natriuretic peptide analogs reveal novel receptor recognition requirements.

J. Lewicki, A. Arfsten, R. Scarborough, 1988, The Journal of biological chemistry.

Characterization of the atrial natriuretic peptide clearance receptor using a vaccinia virus expression vector.

J. Lewicki, D. Schenk, J. G. Porter, 1988, The Journal of biological chemistry.

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

M. Fischer, J. Lewicki, A. Gurney, 2016, Cancer research.

Atrial natriuretic factor (auriculin): structure and biological effects.

J. Laragh, J. Lewicki, M. Volpe, 1985, Journal of clinical hypertension.

Cancer Therapy : Preclinical Anti-DLL 4 HasBroad SpectrumActivity in Pancreatic Cancer DependentonTargetingDLL 4-NotchSignaling inBothTumor and Vasculature Cells

Edward J. Kim, M. Fischer, J. Lewicki, 2012 .

Selective activation of particulate guanylate cyclase by a specific class of porphyrins.

F. Murad, S. Waldman, J. Lewicki, 1984, The Journal of biological chemistry.

Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency

M. Fischer, J. Lewicki, A. Gurney, 2015 .

Properties of purified soluble guanylate cyclase activated by nitric oxide and sodium nitroprusside.

F. Murad, J. Lewicki, H. Brandwein, 1982, Journal of cyclic nucleotide research.

Abstract 3129: Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Chromatography of renin substrate on concanavalin A--Agarose.

J. Lewicki, M. Printz, J. Printz, 1976, Analytical biochemistry.

Abstract 404: Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.

Andrew, J. Laragh, Robert, 1986, The Journal of clinical investigation.

Abstract 3728: Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.

L. Esserman, J. Lewicki, A. Gurney, 2013 .

Abstract 255: Dual targeting of Delta-like ligand 4 (DLL4) and programmed death 1(PD1) inhibits tumor growth and generates enhanced long-term immunological memory

J. Lewicki, A. Gurney, T. Hoey, 2015 .

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

M. Fischer, J. Lewicki, A. Gurney, 2011, Cancer research.

Effect of GTP analogues on purified soluble guanylate cyclase.

F. Murad, S. Waldman, J. Lewicki, 1982, The Journal of biological chemistry.

Purified guanylate cyclase: characterization, iodination and preparation of monoclonal antibodies.

F. Murad, S. Waldman, J. Lewicki, 1980, Journal of cyclic nucleotide research.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types

J. Lewicki, A. Gurney, T. Hoey, 2015 .

Partial purification and characterization of particulate guanylate cyclase from rat liver after solubilization with trypsin.

F. Murad, S. Waldman, J. Lewicki, 1982, Journal of cyclic nucleotide research.